



## In Focus: QIAGEN & QuantiFERON®-TB Gold (QFT®)

### Content:

**2/3** In Focus: QIAGEN & QFT

---

**4** Product Updates

---

**5** Event Updates

---

**6** Publications Update:  
What's new in Gnowee?

---



## In Focus: QIAGEN & QuantiFERON-TB Gold (QFT)

For just over a year, Cellestis and its QuantiFERON platform technology have been operating under the QIAGEN name as *Cellestis, a QIAGEN Company*. Throughout the ongoing merger of Cellestis and QIAGEN systems and the consequent changes for customers, our aim is to continue providing you with the highest quality of global service and support with QuantiFERON products. In this issue we describe what further changes will become visible over the coming months.

For many areas where QuantiFERON is sold directly, the contact details have changed. For a full listing, please visit [www.quantiferon.com](http://www.quantiferon.com) and click the 'Contact Us' tab or, alternatively, please contact your local sales representative. The old Cellestis contacts (phone/email) will be redirected to the relevant QIAGEN contacts for some time to come.

### Customer Orders and Billing

The processes for QuantiFERON customers to place orders has changed. Quotes, invoices, and other documents formerly from Cellestis Customer Service will be shifting to the QIAGEN Customer Care format, but there may be differences regionally at what date these changes have gone or will go into effect. If you have any questions about the content or timing of these changes in your region, please contact your local QuantiFERON representative.

Our global shipping supplier has also changed to United Parcel Service (UPS). If you have any issues with receipt or delivery of your QuantiFERON orders, please contact your local QuantiFERON sales representative.



Figure 1. Cellestis and QIAGEN will be working together to help change the way we look at - and fight - TB.



Figure 2. QIAGEN will be working together to help change the way we look at - and fight - TB.

## Technical Service

Throughout the last year, the QuantiFERON Technical Service team has merged with the QIAGEN Service Solutions team, resulting in a broader global network for customer support and training. The contact details for QuantiFERON-related technical service and

support have been updated to reflect the new organizational setup (online at [www.quantiferon.com](http://www.quantiferon.com)). In addition, new modules for customer technical training will be rolled out soon by the QIAGEN Service Solutions team.

## Branding Update

Many of our brochures, support tools, and conference booths have been updated to reflect new colors and designs of QIAGEN. We will continue to re-brand our materials, websites, and online tools into 2013, and in addition we will be releasing updated

packaging as per local regulatory requirements. In most areas, we expect outer kit packaging to change to blue QIAGEN in early 2013. As we continue the rebranding process, you will see less and less residual Cellestis purple.

## Website

In the last issue of QuantiFERON News, we announced the converging of [www.quantiferon.com](http://www.quantiferon.com) and the Cellestis websites. Whilst the overall goal is to merge the QuantiFERON website into the QIAGEN website, this will be an ongoing process.

Currently, you can access QuantiFERON contacts on [www.qiagen.com](http://www.qiagen.com), and these details will also be listed on [www.quantiferon.com](http://www.quantiferon.com).

For product-related information, please continue to visit [www.quantiferon.com](http://www.quantiferon.com).



## QuantiFERON-TB Gold (QFT) Product Update

We are pleased to announce that the United States FDA has recently approved a formulation update to the QuantiFERON wash buffer. This enhancement is part of our long-term planning for QuantiFERON product improvements. The new preservative, ProClin® 300, is commonly used in in vitro diagnostic assays as a

highly-effective biocide. Customers may note more foaming while using the new QuantiFERON wash buffer, and thus must be particularly attentive to waste levels during plate-washing. If you have any questions about this change, please contact your local QuantiFERON technical representative.

## Coming soon...the QuantiFERON Control Panel

Available as early as February 2013!



**Quantiferon® Control Panel**

**Validated Control**

Developed specifically for QuantiFERON products, the QuantiFERON Control Panel represents a standardized control that will confirm and monitor the accuracy of all QuantiFERON ELISA assays.

Benefits of the QuantiFERON Control Panel:

- **Compliance with Good Laboratory Practices**  
Developed to meet the recommendations of leading laboratory services agencies involved in the accreditation of pathology laboratories!
- **Confidence**  
Will allow monitoring to ensure consistent and reproducible results are obtained between ELISA runs and operators
- **Cost-effective**  
Will help eliminate costs associated with the development, calibration, and validation of "in-house" interferon-gamma (IFN-γ) controls
- **Easy to prepare and use**  
Comprises of a set of 3 lyophilized IFN-γ controls, each with assigned concentration values within the linear range of the QuantiFERON ELISA, that are processed in the same way as patient samples

**QIAGEN®**

[www.QuantiFERON.com](http://www.QuantiFERON.com)

Figure 3. QIAGEN Control Panel Flyer

Developed specifically for QuantiFERON products, the QuantiFERON Control Panel is a standardized control for use in all QuantiFERON ELISA assays, including:

- QuantiFERON®-TB Gold (QFT®)
- QuantiFERON®-CMV\*

The QuantiFERON Control is cost-effective alternative to the development and use of any "in-house" control and will:

- Ensure that consistent and accurate results, within the linear range of the QuantiFERON ELISA platform, are being obtained
- Assist in the identification of any random or systematic error.

The QuantiFERON Control Panel will be available as a CE marked product in January 2013. We anticipate approval for using this product in the United States in early 2013.

\* QuantiFERON®-CMV is CE Marked for commercial use in Europe. It is not United States FDA-approved at this time and is limited to investigational use only in the United States. We anticipate United States FDA approval for this product in 2013.

## 3rd IGRA Symposium Update

### Continuing Medical Education (CME) activity coming soon

Several activities have stemmed from the 3rd IGRA Symposium in Hawaii earlier in 2012. Proceedings from the meeting have been submitted for publication and highlight key topics of interest. These include the paradigm that latent TB may not be as 'latent' as once thought as well as interpretation of IGRAs for serial screening in healthcare workers. These topics are

also the focus of an upcoming video-based University of California San Diego (UCSD) CME activity, which has been made possible through an educational grant from Cellestis, a QIAGEN Company. You can access the Hawaii meeting abstracts on <http://cme.ucsd.edu/igras/syllabus.html>.



Figure 4. The 3rd Global Symposium on IGRAs 2012 was sponsored by Cellestis.

## TB and TNF- $\alpha$ inhibitors: CME Webcast Series

### Educational activity by Cleveland Clinic continues

Earlier in 2012, Cellestis funded through an educational grant a Cleveland Clinic Foundation CME activity entitled, "Tuberculosis Testing in the 21st Century: The Role of Interferon-Gamma Release Assays." The webcast event continues through the start of 2013, so be sure to visit today.

[www.clevelandclinicmeded.com/online/tb-testing](http://www.clevelandclinicmeded.com/online/tb-testing)

The educational activities are part of QIAGEN's initiative to promote and support TB screening for patients with rheumatoid arthritis prior to commencing tumor necrosis factor alpha (TNF- $\alpha$ ) inhibitor therapy. QIAGEN's TB & TNF Clinical Review is currently being updated to include the new US guidelines on TB screening in these populations. You can find this and more on [www.cellestis.com/TBAndTNF](http://www.cellestis.com/TBAndTNF).



Figure 5. Cleveland Clinic Foundation CME activity sponsored by Cellestis.



## Publications Update: What's new in Gnowee?

Gnowee is your complete QuantiFERON-TB Gold library where you can find complementary clinical abstracts, guidelines, presentations, and more. Below is a listing of the new abstracts in Gnowee.

### Gnowee: What's with the name?

When we were putting the clinical reference tool together, we were looking for a name that symbolized a growing body of scientific knowledge about TB and QFT in particular. Enter Gnowee (pronounced no-ee). Aboriginal Australian Dreamtime legend tells that Gnowee is a goddess who holds her burning torch (the rising sun) to the sky to shed light on the land so she can search for her lost child. In a very small way, we hope Gnowee is a proverbial torch for QFT – that it provides users with the knowledge to 'Change the way the world looks at TB.'

#### Journal Article

Aberg J, Kaplan J, Libman H, Emmanuel P, Anderson JR Stone V, Oleske J, Currier J, Gallant J; HIV Medicine Association of the Infectious Diseases Society of America. Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis.* 2009 Sep 1;49(5):651-81.

Ahmadinejad Z, Azmoudeh Ardalan F, Razaqi M, Davoudi S, Jafarian A. QuantiFERON-TB Gold In-Tube test for diagnosis of latent tuberculosis (TB) infection in solid organ transplant candidates: a single-center study in an area endemic for TB. *Transpl Infect Dis.* 2012 Nov 23. doi: 10.1111/tid.12027. [Epub ahead of print]

Ahmadinejad Z, Azmoudeh Ardalan F, Safy S, Nikbakht G. Diagnosis of latent tuberculosis infection in candidates for kidney transplantation (comparison of two tests). *Acta Med Iran.* 2012;50(5):305-10.

Akkerman O, van der Loo K, Nijmeijer D, van der Werf T, Mulder B, Kremer K, van Soolingen D, van der Zanden A. *Mycobacterium bovis* infection in a young Dutch adult: transmission from an elderly human source? *Med Microbiol Immunol.* 2012 Aug;201(3):397-400.

Alimohammadian M, Jones S, Darabi H, Riazirad F, Ajdary S, Shabani A, Rezaee M, Mohebbali M, Hosseini Z, Modabber F. Assessment of interferon- levels and leishmanin skin test results in persons recovered for leishmaniasis. *Am J Trop Med Hyg.* 2012 Jul ;87(1):70-5.

Anibarro L, Trigo M, Feijó D, Ríos M, Palomares L, Pena A, Núñez M, Villaverde C, González-Fernández A. Value of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to *M. tuberculosis*. *BMC Infect Dis.* 2012 Aug ;12:195

Arlehamn C, Sidney J, Henderson R, Greenbaum J, James E, Moutafsi M, Coler R, McKinney D, Park D, Taplitz R, Kwok W, Grey H, Peters B, Sette A.

Arlehamn C, Sidney J, Henderson R, Greenbaum J, James E, Moutafsi M, Coler R, McKinney D, Park D, Taplitz R, KwDenkinger CM, Pai M, Patel M, Menzies D. Interferon-gamma release assay for treatment monitoring of active tuberculosis - An explosion in the spaghetti factory. *J Clin Microbiol.* 2012 Nov 21. [Epub ahead of print]

Ashenafi S, Aderaye G, Zewdie M, Raqib R, Bekele A, Magalhaes I, Lema B, Habtamu M, Rekha RS, Aseffa G, Maeurer M, Aseffa A, Svensson M, Andersson J, Brighenti S. BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients. *Thorax.* 2012 Aug 24. [Epub ahead of print]

Banfield S, Pascoe E, Thambiran A, Siafarikas A, Burgner D. Factors associated with the performance of a blood-based interferon-gamma release assay in diagnosing tuberculosis. *PLoS One.* 2012 Jun;7(6):e38556. Epub 2012 Jun 12.

Bansal R, Gupta A, Gupta V, Dogra M, Sharma A, Bamberg P. Tubercular serpiginous-like choroiditis presenting as multifocal serpiginoid choroiditis. *Ophthalmology.* 2012 Nov;119(11):2334-42

Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, Fiori G, Li Gobbi F, Mantella A, Benucci M, Prignano F, Pimpinelli N, Cerinic M, Girardi E, Bartoloni A. Serial QuantiFERON TB-Gold in tube testing during LTBI therapy in candidates for TNFi treatment. *J Infect.* 2012 Oct 24. [Epub ahead of print]

Bautista J, Banaei N. Sensitivity of QuantiFERON-TB GOLD In-Tube for diagnosis of recent versus remote *M. tuberculosis* infection. *Diagn Microbiol Infect Dis.* 2012 Jul;73(3):257-9. Epub 2012 Apr

Bendayan D, Hender A, Litman K, Polansky V. The role of interferon-gamma release assays in the diagnosis of active tuberculosis. *Isr Med Assoc J.* 2012 Feb;14(2):107-10.

## Journal Article

Bentley T, Catanzaro A, Ganiats T. Implications of the impact of prevalence on test thresholds and outcomes: lessons from tuberculosis. *BMC Res Notes*. 2012 Oct 10;5(1):563. [Epub ahead of print]

Bentley T, Catanzaro A, Ganiats T. Implications of the impact of prevalence on test thresholds and outcomes: lessons from tuberculosis. *BMC Res Notes*. 2012 Oct 10;5(1):563.

Bergot E, Haustraete E, Malbrun B, Magnier R, Salaün MA, Zalzman G. Observational study of QuantiFERON®-TB gold in-tube assay in tuberculosis contacts in a low incidence area. *PLoS One*. 2012;7(8):e43520

Bhubhar S, Biswas J. Nested PCR-positive tubercular ampiginous choroiditis: a case report. *Ocul Immunol Inflamm*. 2012 Aug;20(4):303-5. Epub 2012 May 23

Bihari S, Cavalcanti N, Correia J, Alves G, Souza E, Brabin B, Cuevas L. Interferon gamma-induced protein-10 concentrations in children with previous tuberculosis infections and disease. *Pediatr Infect Dis J*. 2012 Oct;31(10):1089-91.

Bodro M, Sabé N, Santín M, Cruzado J, Lladó L, González-Costello J, Carratalà J. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. *Transplant Proc*. 2012 Nov;44(9):

Borgia P, Cambieri A, Chini F, Coltella L, Delogu G, Di Rosa E, Fadda G, Giorgi Rossi P, Girardi E, Goletti D, Guasticchi G, Morrone A, Pezzotti P, Romagnoli C, Sacerdote M, Russo C, Villani A, Zarelli L. Suspected transmission of tuberculosis in a maternity ward from a smear-positive nurse: preliminary results of clinical evaluations and testing of neonates potentially exposed, Rome, Italy, 1 January to 28 July 2011. *Euro Surveill*. 2011 Oct 6;16(40). pii: 19984

Bowman J, Thijsen S, Bossink A. Improving the timeframe between blood collection and interferon gamma release assay using T-Cell Xtend. *J infect* 2012 64, 197-203

Bugiani M, Bonora S, Carosso A, Piccioni P, Cavallero M, Mondo A, Ghisetti V. The effect of antituberculosis treatment on interferon-gamma release assay results. *Monaldi Arch Chest Dis*. 2011 Dec;75(4):215-9.

Buonsenso D, Lancella L, Delogu G, Krzysztofciak A, Testa A, Ranno O, D'Alfonso P, Valentini P. A twenty-year retrospective study of pediatric tuberculosis in two tertiary hospitals in Rome. *Pediatr Infect Dis J*. 2012 Oct;31(10):1022-6.

Cantisano Bohórquez S, Ortega N. Immunological monitoring strategies for cytomegalovirus infection. [Immune-based therapies]. *Enferm Infecc Microbiol Clin*. 2011 Dec. ;29 Suppl 6:28-32.

Cassone A, Cauda R, De Maria A. High rate of Quantiferon positive and tuberculin negative tests in infants born at a large Italian University Hospital in 2011: a cautionary hypothesis. *Pathog Glob Health*. 2012. Mar;106(1):8-11.

Castell S, Bauer T, Diel R, Hedrich A, Magdorf K, Rüsche-Gerdes S, Schaberg T, Loddenkemper R. [International Standards of Tuberculosis Care (ISTC) - Comments from the German Point of View]. *Pneumologie*. 2012 Apr;66(4):240-9. Epub 2012 Mar 13.

Chiappini E, Accetta G, Bonsignori F, Boddi V, Galli L, Biggeri A, De Martino M. Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a systematic review and meta-analysis. *Int J Immunopathol Pharmacol*. 2012 Jul-Sep;25(3):557-64.

Chan P, Yang C, Chang L, Wang K, Lu B, Lu C, Shao P, Hsueh P, Fang C, Huang L. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. *Int J Tuberc Lung Dis*. 2012 May;16(5):633-8

Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF inhibitors: the utility of IFN $\gamma$  assay. *Ann Rheum Dis*. 2012 Feb;71(2):231-7. Epub 2011 Oct 21.

Chan P, Yang C, Chang L, Wang K, Kuo Y, Lin C, Lee S, Hsueh P, Fang C, Huang L. Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. *Thorax*. 2012 Sep 27. [Epub ahead of print]

Chiappini E, Bonsignori F, Accetta G, Boddi V, Galli L, Biggeri A, De Martino M. Interferon- $\gamma$  release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a literature review. *Int J Immunopathol Pharmacol*. 2012 Apr-Jun;25(2):335-43.

Chiappini E, Fossi F, Bonsignori F, Sollai S, Galli L, de Martino M. Utility of interferon- $\gamma$  release assay results to monitor anti-tubercular treatment in adults and children. *Clin Ther*. 2012 May;34(5):1041-8. Epub 2012 Apr 17. Review.

Cho K, Cho E, Kwon S, Im S, Sohn I, Song S, Kim H, Kim S. Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis. *Tuberc Respir Dis (Seoul)*. 2012 May;72(5):416-25.

Clari M, Muñoz-Cobo B, Solano C, Benet I, Costa E, Remigia M, Bravo D, Amat P, Navarro D. Performance of the QuantiFERON(R)-cytomegalovirus (CMV) Assay for Detecting and Estimating the Magnitude and Functionality of the CMV-Specific IFN- $\gamma$  CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients. *Clin Vaccine Immunol*. 2012 May;19(5):791-6

Cobelens F, van den Hof S, Pai M, Squire S, Ramsay A, Kimerling M; on behalf of the Evidence for Scale-up Group. Which New Diagnostics for Tuberculosis, and When? *J Infect Dis*. 2012 May 15;205 Suppl 2:S191-8. Epub 2012 Apr 3.

Colbert G, Richey D, Schwartz J. Widespread tuberculosis including renal involvement. *Proc (Bayl Univ Med Cent)*. 2012 Jul;25(3):236-9

Critselis E, Amanatidou V, Syridou G, Spyridis N, Mavrikou M, Papadopoulos N, Tsolia M. The Effect of Age on Whole Blood Interferon-Gamma Release Assay Response among Children Investigated for Latent Tuberculosis Infection. *J Pediatr*. 2012 Oct;161(4):632-8. Epub 2012 May 24.

Dagnew A, Hussein J, Abebe M, Zewdie M, Mihret A, Bedru A, Chanyalew M, Yamuah L, Medhin G, Bang P, Doherty T, Hailu A, Aseffa A. Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth. *BMC Res Notes*. 2012 Aug 7;5:415.

Darugar A, Mathian A, Lehoang P, Bodaghi B. Acute posterior multifocal placoid pigment epitheliopathy as the initial manifestation of sarcoidosis. *J Ophthalmic Vis Res*. 2011 Oct;6(4):338-43.

## Publications Update: What's new in Gnowee? continued

### Journal Article

Del Campo M, Fouad H, Solís-Bravo M, Sánchez-Uriz M, Mahillo-Fernández I, Esteban J. Cost-effectiveness of different screening strategies (single or dual) for the diagnosis of tuberculosis infection in healthcare workers. *Infect Control Hosp Epidemiol*. 2012 Dec ;33(12):1226-34

Denkinger CM, Pai M, Patel M, Menzies D. Interferon-gamma release assay for treatment monitoring of active tuberculosis - An explosion in the spaghetti factory. *J Clin Microbiol*. 2012 Nov 21. [Epub ahead of print]

Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and Positive Predictive Value of a Whole-Blood Interferon-g Release Assay for Developing Active Tuberculosis. *Am J Respir Crit Care Med*. 2011 Jan 1;183(1):88-95

Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. *Chest*. 2012 July142(1):63-75.

Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). *J Immunol*. 2012 May 15;188(10):5020-31. Epub 2012 Apr 13.

Eldin EN, Omar A, Khairy M, Mekawy AH, Ghanem MK. Diagnostic value of ex vivo pleural fluid interferon-gamma versus adapted whole-blood quantiferon-TB gold in tube assays in tuberculous pleural effusion. *Ann Thorac Med*. 2012 Oct;7(4):220-5.

Fan L, Chen Z, Hao X, Hu Z, Xiao H. Interferon-Gamma Release Assays for the diagnosis of Extrapulmonary Tuberculosis: A Systematic Review and Meta-Analysis. *FEMS Immunol Med Microbiol*. 2012 Aug;65(3):456-66

Fong K, Tomford J, Teixeira L, Fraser T, Vanduin D, Yen-Lieberman B, Gordon S, Miranda C. Challenges of Interferon-gamma Release Assay Conversions in Serial Testing of Health Care Workers in a Tuberculosis Control Program. *Chest*. 2012 January 19 epub ahead of print

Fournier A, Antoun F, Larnaudie S. Recent latent tuberculous infection (LTBI) in different sub-groups of contacts]. *Rev Mal Respir*. 2012 Nov;29(9):1079-87. doi: 10.1016/j.rmr.2012.06.005. Epub 2012 Aug 3. French.

Freeman J, Marshall R, Newton S, Austin P, Taylor S, Chew T, Gavaghan S, Roberts S. Screening for Mycobacterium tuberculosis infection among healthcare workers in New Zealand: prospective comparison between the tuberculin skin test and the QuantiFERON-TB Gold In-Tube assay. *N Z Med J*. 2012 Feb 10;125(1349):21-9.

García-Gasalla M, Fernández-Baca V, Juan-Mas A, Payeras-Cifre A, Cifuentes-Luna C, Taberner-Ferrer R, Riera-Oliver J, Ros-Villamajó I, Navarro-Fernández V, Morey Torrandell C, Gallegos-Alvarez C, Mir-Villadrich I. Use of Quantiferon-TB-Gold in Tube(®) test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice. *Enferm Infecc Microbiol Clin*. 2012 Aug 16. [Epub ahead of print]

Gao Y, Ou Q, Huang F, Wang S, Shen L, Shen Y, Wu J, Zheng J, Weng X, Zhang W, Shao L. Improved diagnostic power by combined interferon-gamma release assay and nested-PCR in tuberculous pleurisy in high tuberculosis prevalence area. *FEMS Immunol Med Microbiol*. 2012 Sep 24. [Epub ahead of print]

Gao Y, Ou Q, Huang F, Wang S, Shen L, Shen Y, Wu J, Zheng J, Weng X, Zhang W, Shao L. Improved diagnostic power by combined interferon-gamma release assay and nested-PCR in tuberculous pleurisy in high tuberculosis prevalence area. *FEMS Immunol Med Microbiol*. 2012 Dec;66(3):393-8. doi: 10.1111/1574-695X.12006.

Gaur R, Suhosk M, Banaei N. In Vitro Immunomodulation of a Whole Blood IFN- Release Assay Enhances T Cell Responses in Subjects with Latent Tuberculosis Infection. *PLoS One*. 2012. ;7(10):e48027. Epub 2012 Oct 29.

Goswami N, Hecker E, Vickery C, Ahearn M, Cox G, Holland D, Naggie S, Piedrahita C, Mosher A, Torres Y, Norton B, Suchindran S, Park P, Turner D, Stout J. Geographic Information System-based Screening for TB, HIV, and Syphilis (GIS-THIS): A Cross-Sectional Study. *PLoS One*. 2012 ;7(10):e46029.

Guglielmetti L, Conti M, Cazzadori A, Lo Cascio G, Sorrentino A, Concia E. Diagnostic sensitivity of QuantiFERON-TB Gold In-Tube and tuberculin skin test in active tuberculosis: influence of immunocompromission and radiological extent of disease. *Infez Med*. 2012 Mar 1;20(1):16-24.

Haldar P, Thuraisingam H, Patel H, Pereira N, Free R, Entwisle J, Wiselka M, Hoskyns E, Monk P, Barer M, Woltmann G. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. *Thorax*. 2012 Sep 6. [Epub ahead of print]

Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. *Arthritis Res Ther*. 2012 Jun 18;14(3):R147. doi: 10.1186/ar3882

He G, Wang L, Chai S, Klana J, Cheng S, Ren Y, Ren L, Gao F, Li Y, He G, Li J, Wang Y, Rao C, Varma J. Risk factors associated with tuberculosis infection among health care workers in Inner Mongolia, China. *Int J Tuberc Lung Dis*. 2012 Nov;16(11):1485-91. Epub 2012 Sep 7.

Helwig U, Müller M, Hedderich J, Schreiber S. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. *J Crohns Colitis*. 2012 May;6(4):419-24

Higuchi K, Sekiya Y, Igari H, Watanabe A, Harada N. Comparison of specificities between two interferon-gamma release assays in Japan. *Int J Tuberc Lung Dis*. 2012 Sep ;16(9):1190-2. Epub 2012 Jun 28

Hsu D, Zauanders J, Plit M, Leeman C, Ip S, Lampornsin T, Pett S, Bailey M, Amin J, Ubolyam S, Avihingsanon A, Ananworanich J, Ruxrungtham K, Cooper D, Kelleher A. A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays. *Tuberculosis (Edinb)*. 2012 Jul;92(4):321-7. Epub 2012 Apr 26.



## Journal Article

Jeong Y, Yoon S, Koo H, Lim H, Lee J, Lee S, Yang S, Yoo C, Kim Y, Han S, Yim J. Positive tuberculin skin test or interferon-gamma release assay in patients with radiographic lesion suggesting old healed tuberculosis. *J Korean Med Sci.* 2012 Jul;27(7):761-6. Epub 2012 Jun 29.

Jo K, Jeon K, Kang Y, Koh W, Kim K, Kim Y, Yoo K, Lee S, Yim J, Choi S, Choi W, Choi J, Hwang Y, Shim T. Poor correlation between tuberculin skin tests and interferon- $\gamma$  assays in close contacts of patients with multidrug-resistant tuberculosis. *Respirology.* 2012 Oct;17(7):

Joshi M, Monson T, Woods G. Use of interferon-gamma release assays in a health care worker screening program: experience from a tertiary care centre in the United States. *Can Respir J.* 2012 Mar-Apr;19(2):84-8.

Jung da H, Jo KW, Shim TS. Prevalence of Latent Tuberculosis Infection among Medical Students in South Korea. *Tuberc Respir Dis (Seoul).* 2012 Oct;73(4):219-23. doi: 10.4046/trd.2012.73.4.219. Epub 2012 Oct 31.

Kabeer BS, Sikhmani R, Raja A. Comparison of interferon gamma-inducible protein-10 and interferon gamma-based QuantiFERON TB Gold assays with tuberculin skin test in HIV-infected subjects. *Diagn Microbiol Infect Dis.* 2011 Nov;71(3):236-43.

Kakkar F, Allen U, Ling D, Pai M, Kitai I. Tuberculosis in children: New diagnostic blood tests. [Article in English, French] *Paediatr Child Health.* 2010 Oct;15(8):529-38

Kamiya H, Ikushima S, Kondo K, Satake K, Inomata M, Moriya A, Ando T. Diagnostic performance of interferon-gamma release assays in elderly populations in comparison with younger populations. *J Infect Chemother.* 2012 Oct 30. [Epub ahead of print]

Kang JY, Rhee CK, Kang NH, Kim JS, Yoon HK, Song JS. Clinical Utility of Two Interferon-gamma Release Assays on Pleural Fluid for the Diagnosis of Tuberculous Pleurisy. *Tuberc Respir Dis (Seoul).* 2012 Sep;73(3):143-50. doi: 10.4046/trd.2012.73.3.143. Epub 2012 Sep 28.

Kardos M, Kimball A. Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting. *J Am Acad Dermatol.* 2012 Jan;66(1):148-52.

Kelsen J, Bartels L, Dige A, Hvas C, Frings-Meuthen P, Boehme G, Thomsen M, Fenger-Grøn M, Dahlerup J. 21 Days head-down bed rest induces weakening of cell-mediated immunity - Some spaceflight findings confirmed in a ground-based analog. *Cytokine.* 2012 Aug;59(2):403-9.

Kim J, Cho S, Han M, Choi C, Kim T, Jun J, Bae S, Yoo D, Sung Y. Factors Influencing Discrepancies Between the QuantiFERON-TB Gold in Tube Test and the Tuberculin Skin Test in Korean Patients with Rheumatic Diseases. *Semin Arthritis Rheum.* 2012 Aug 1. [Epub ahead of print]

Kim KH, Lee SW, Chung WT, Kim BG, Woo KS, Han JY, Kim JM. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. *Korean J Lab Med.* 2011 Oct;31(4):271-8. Epub 2011 Oct 3.

Kim S, Jung G, Kim K, Chang J, Kim S, Kim S, Kang Y, Joo D. Comparison of the tuberculin skin test and interferon- $\gamma$  release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. *Infection.* 2012 Jul 17. [Epub ahead of print]

Kim S, Kim Y, Lee H, Cho J, Kim H, Uh Y, Kim Y, Kim H, Cho S, Jeon B, Lee H. Interferon gamma mRNA quantitative real-time polymerase chain reaction for the diagnosis of latent tuberculosis: a novel interferon gamma release assay. *Diagn Microbiol Infect Dis.* 2012 Oct 24. [Epub ahead of print]

Kim S, Park M, Kim Y, Kim S, Chang J, Kang Y. Conversion rates of an interferon- release assay and the tuberculin skin test in the serial monitoring of healthcare workers. *Infection.* 2012 Oct 27. [Epub ahead of print]

Kim S, Park M, Kim Y, Kim S, Chang J, Lee H, Cho S, Kang Y. The Responses of Multiple Cytokines Following Incubation of Whole Blood from TB Patients, Latently Infected Individuals and Controls with the TB Antigens ESAT-6, CFP-10 and TB7.7. *Scand J Immunol.* 2012 Dec;76(6):580-6

Klein M, Jarosová K, Forejtová S, Be vá R, Sedová L, Pavelka K, Simková G, Svobodová R, Hviscová K, Mann H, P tová I, Vencovský J. QuantiFERON TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. *Clin Exp Rheumatol.* 2012 Oct 24. [Epub ahead of print]

Kleinert S, Tony H, Krueger K, Detert J, Mielke F, Rockwitz K, Schwenke R, Burmester G, Diel R, Feuchtenberger M, Kneitz C. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon- $\gamma$  release assays under real-life conditions. *Ann Rheum Dis.* 2012 Nov;71(11):Epub 2012 May 14.

Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Usefulness of tuberculin skin test and three interferon-gamma release assays for the differential diagnosis of pulmonary tuberculosis. *Intern Med.* 2012 May;51(10):1199-205. Epub 2012 May 15.

Kowada A. Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening. *Mol Diagn Ther.* 2012 Jun;16(3):181-90.

Kurahara Y, Tachibana K, Tezuka K, Shimizu S, Kitaichi M, Hayashi S, Suzuki K. Kikuchi-Fujimoto disease mimicking tuberculous lymphadenitis. *Intern Med.* 2012;51(14):1927-30.

Kuznetcova T, Sauty A, Herbert C. Uveitis with occult choroiditis due to *Mycobacterium kansasii*: limitations of interferon-gamma release assay (IGRA) tests (case report and mini-review on ocular non-tuberculous mycobacteria and IGRA cross-reactivity). *Int Ophthalmol.* 2012 Oct;32(5):499-506. Epub 2012 Jun 2

## Publications Update: What's new in Gnowee? continued

### Journal Article

Lange B, Vavra M, Kern W, Wagner D. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA [Short communication]. *Int J Tuberc Lung Dis.* 2012 Apr;16(4):492-5

Larcher C, Frizzera E, Pretto P, Lang M, Sonnleitner N, Huemer H. Immunosurveillance for *Mycobacterium tuberculosis* of health care personnel in a third level care hospital. *Med Lav.* 2012 Jan-Feb;103(1):26-36.

Lee J, Lee S, Yoo S, Cha S, Won D, Park J, Lee W, Kim C. Clinical value of whole-blood interferon-gamma assay in patients with suspected pulmonary tuberculosis and AFB smear- and polymerase chain reaction-negative bronchial aspirates. *Diagn Microbiol Infect Dis.* 2012 Jul;73(3):252-6. Epub 2012 Apr 26.

Lee J, Lee S, Won D, Cha S, Park J, Kim C. Comparison of whole-blood interferon- $\gamma$  assay and flow cytometry for the detection of tuberculosis infection. *J Infect.* 2012 Sep 23. [Epub ahead of print]

Lee S, Lee S, Yim J. Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. *Infection.* 2012 Aug;40(4):431-5.

Ling I, Crépeau C, Dufresne M, Khan S, Quach C, Dendukuri N, Schwartzman K, Menzies D, Lands L, Pai M. Evaluation of the Impact of Interferon- Gamma Release Assays on Management of Childhood Tuberculosis. *Pediatr Infect Dis J.* 2012 Jul 23. [Epub ahead of print]

Llorenç V, González-Martin J, Keller J, Rey A, Pelegrín L, Mesquida M, Adán A. Indirect supportive evidence for diagnosis of tuberculosis-related uveitis: from the tuberculin skin test to the new interferon gamma release assays. *Acta Ophthalmol.* 2012 Oct 8 epub ahead of print

Machingaidze S, Verver S, Mulenga H, Abrahams D, Hatherill M, Hanekom W, Hussey G, Mahomed H. Predictive Value of Recent QuantiFERON Conversion for Tuberculosis Disease in Adolescents. *Am J Respir Crit Care Med.* 2012 Nov 15;186(10):1051-6

Maitra R, Bowling T, Venkatesan P, Maxwell-Armstrong C. Crohn's disease or TB--the perennial question and diagnostic pitfalls. *BMJ Case Rep.* 2012 Apr 2

Mandalakas AM, van Wyk S, Kirchner HL, Walzl G, Cotton M, Rabie H, Kriel B, Gie RP, Schaaf HS, Hesselning AC. Detecting Tuberculosis Infection in HIV-Infected Children: A Study of Diagnostic Accuracy, Confounding and Interaction. *Pediatr Infect Dis J.* 2012 Nov 28. [Epub ahead of print]

Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. Assessment of cytomegalovirus specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. *Clin Infect Dis.* 2012 Nov 29. [Epub ahead of print]

Mathur G, Biswas J. Systemic associations of anterior uveitis in a tertiary care ophthalmic centre in south India. *Int Ophthalmol.* 2012 Oct.32(5):417-21. Epub 2012 May 9

Matsumoto K, Miyake Y, Arima K, Komukai J, Danno K, Yoshida H, Hirota S, Koda S, Terakawa K, Shimouchi A. [Examination of onset cases in contact investigation]. *Kekkaku.* 2012 Feb;87(2):35-40.

McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O'Grady J, Pletschette M, Ditiu L, Atun R, Zumla A. Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities. *J Infect Dis.* 2012 Nov. 15;205 Suppl 2:S147-58.

Min JY, Bang SY, Min SY, Lee DS, Kim BS, Kim JE, Lee ES, Pyo JY, Sohn JW, Kim TH, Lee HS. *Tuberc Respir Dis (Seoul).* 2012 Oct;73(4):234-8. doi: 10.4046/trd.2012.73.4.234. Epub 2012 Oct 31.

Metcalfe J, Cattamanchi A, McCulloch C, Lew J, Ha N, Graviss. Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice. *EA. Am J Respir Crit Care Med.* 2012 Oct 26. [Epub ahead of print]

Meyssonnier V, Guihot A, Chevet K, Veziris N, Assoumou L, Bourgarit A, Costagliola D, Caumes E, Carcelin G. Performance of QuantiFERON® for the diagnosis TB. *Med Mal Infect.* 2012 Nov 6. [Epub ahead of print]

Miloti D, Popovi -Grle S, Katalini -Jankovi V, Simunovi A. Comparison of new and old tests for the diagnosis of latent tuberculosis infection (quantiferon and TST). *Lijec Vjesn.* 2011 Nov-Dec;133(11-12):396-402.

Moon S, Lee S, Choi S, Kim Y, Woo J, Yoon D, Suh C, Kim D, Lee J, Lee J, Lee K, Kim S. Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. *Transpl Infect Dis.* epub 2012 Jul 23.

Mulder C, van Deutekom H, Huisman E, Toumanian S, Koster B, Meijer-Veldman W, van Loenhout-Rooyackers J, Appel M, Arend S, Borgdorff M, van Leth F. Role of QuantiFERON-TB Gold In-Tube in screening new immigrants for tuberculosis infection. *Eur Respir J.* 2012 Apr 20. [Epub ahead of print]

Nakasono E, Mato N, Nakayama M, Bando M, Sugiyama Y. A case of pulmonary tuberculosis with false negative QuantiFERON TB-2G Test. *Kekkaku.* 2012 Jan;87(1):9-13.

Nienhaus A, Schablon A, Tripoldi D, Torres Costa J. [The prevalence of latent tuberculosis infections among health-care workers--a three-country comparison]. *Pneumologie.* 2011 Dec;65(12):726-9. Epub 2011 Oct 17.

## Journal Article

Nienhaus A, Schablon A, Costa J, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. *BMC Health Serv Res*. 2011 Sep 30;11:247.

Nissen T, Rose M, Kimaro G, Bygbjerg I, Mfinanga SG, Ravn P. Challenges of loss to follow-up in tuberculosis research. *PLoS One*. 2012;7(7):e40183

Nguyen M, Green-McKenzie J. What are the differences between the tuberculin skin test and the QuantiFERON-TB Gold test? *J Occup Environ Med*. 2012 Sept;54(9):1177-8.

Okimoto N, Nanba F, Kurihara T, Miyashita N. The positive response rate with QuantiFERON-TB GOLD In-Tube in patients with *Mycobacterium avium* complex. *Kekkaku*. 2012 Apr;87(4):337-9.

O'Neal W, Winters M, Augustino K, Fang X, Cook P. TB screening in an HIV clinic: how interferon-gamma assays improve screening compliance. *Int J Tuberc Lung Dis*. 2012 May;16(5):707.

Onur H, Hatipo lu S, Arica V, Hatipo lu N, Arica SG. Comparison of quantiferon test with tuberculin skin test for the detection of tuberculosis infection in children. *Inflammation*. 2012 Aug;35(4):1518-24.

Pareek M, Bond M, Shorey J, Seneviratne S, Guy M, White P, Lalvani A, Kon O. Community-based evaluation of immigrant tuberculosis screening using interferon  $\gamma$  release assays and tuberculin skin testing: observational study and economic analysis. *Thorax*. 2012 Jun 12. [Epub ahead of print]

Park J, Lee J, Kim M, Lee C, Yoon H, Lee S, Yoo C, Kim Y, Han S, Yim J. Monthly follow-ups of interferon- release assays among healthcare workers in contact with TB patients. *Chest*. 2012 May 3. [Epub ahead of print]

Parsons S, Menezes A, Cooper D, Walzl G, Warren R, van Helden P. Development of a diagnostic gene expression assay for tuberculosis and its use under field conditions in African buffaloes (*Syncerus caffer*). *Vet Immunol Immunopathol*. 2012 Aug 15;148(3-4):337-42. Epub 2012 May 19.

Paxton G, Sangster K, Maxwell E, McBride C, Drewe R. Post-arrival health screening in Karen refugees in Australia. *PLoS One*. 2012 May;7(5):4. Epub 2012 May 31.

Perez-Guzman C, Serna-Vela F, Vargas M. When TB associates with diabetes. *Expert Rev Anti Infect Ther*. 2012 ;10(7):727-8.

Perry S, Chang A, Sanchez L, Yang S, Haggerty T, Parsonnet J. The immune response to tuberculosis infection in the setting of *Helicobacter pylori* and helminth infections. *Epidemiol Infect*. 2012 Sep 7:1-12. [Epub ahead of print]

Pollock K M, Tam H, Grass L, Bowes S, Cooke G, Pareek M, Montamat-Sicotte D, Kapembwa M, Taylor G, Lalvani A. Comparison of screening strategies to improve the diagnosis of latent tuberculosis infection in the HIV-positive population: a cohort study. *BMJ Open*. 2012 Jan. 1;2(2):e000762.

Ramos J, Masiá M, Rodríguez J, López C, Padilla S, Robledano C, Navarro-Blasco F, Matarredona J, García-Sepulcre M, Gutiérrez F. Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases. *Clin Exp Med*. 2012 Jun 27. [Epub ahead of print]

Ramos J, Robledano C, Masiá M, Belda S, Padilla S, Rodríguez J, Gutierrez F. Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. *BMC Infect Dis*. 2012 Jul 31;12:169.

Riazi S, Zeligs B, Yeager H, Peters S, Benavides G, Di Mita O, Bellanti J. Rapid diagnosis of *Mycobacterium tuberculosis* infection in children using interferon-gamma release assays (IGRAs). *Allergy Asthma Proc*. 2012 May-Jun;33(3):217-26.

Ringrose J, Sanche S, Taylor-Gjevne R. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy. *Clin Exp Rheumatol*. 2011 Sep-Oct;29(5):790-4. Epub 2011 Oct 31.

Ringshausen F, Schablon A, Nienhaus A. Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. *J Occup Med Toxicol*. 2012 Jun 18;7(1):6.

Rogerson T, Chen S, Kok J, Hayen A, Craig J, Sud K, Kable K, Webster A. Tests for Latent Tuberculosis in People With ESRD: A Systematic Review. *Am J Kidney Dis*. 2012 Oct 13. [Epub ahead of print]

Rose M, Kimaro G, Kroidl I, Hoelscher M, Bygbjerg I, Mfinanga G, Ravn P. Evaluation of Quantiferon Microtube, using 0.9 mL blood, for diagnosing TB infection. *Eur Respir J*. 2012 Aug 9. [Epub ahead of print]

Rose M, Kimaro G, Nissen T, Kroidl I, Hoelscher M, Bygbjerg I, Mfinanga S, Ravn P. QuantiFERON®-TB gold in-tube performance for diagnosing active tuberculosis in children and adults in a high burden setting. *PLoS One*. 2012;7(7):e37851

Roy R, Sotgiu G, Altet-Gómez N, Tsolia M, Ruga E, Velizarova S, Kampmann B. Identifying predictors of interferon- release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guérin? a pTB-NET collaborative study. *Am J Respir Crit Care Med*. 2012 Aug 15;186(4):378-84. Epub 2012 Jun 14.

Rubbo P, Nagot N, Le Moing V, Babet M, Bourdin A, Nogue E, Bollere K, Vendrell J, Van De Perre P, Tuillon E. Multi-cytokine detection improves latent tuberculosis diagnosis in healthcare workers. *J Clin Microbiol*. 2012 May;50(5):1711-7.

Rutherford M, Hill P, Maharani W, Apriani L, Sampurno H, van Crevel R, Ruslami R. Risk factors for *Mycobacterium tuberculosis* infection in Indonesian children living with a sputum smear-positive case. *Int J Tuberc Lung Dis*. 2012 Dec;16(12):1594-9

## Publications Update: What's new in Gnowee? continued

### Journal Article

Rutherford M, Nataprawira M, Yulita I, Apriani L, Maharani W, van Crevel R, Hill PC, Alisjahbana B. QuantiFERON®-TB Gold In-Tube assay vs. tuberculin skin test in Indonesian children living with a tuberculosis case. *Int J Tuberc Lung Dis.* 2012 Apr;16(4):496-502.

Saidenberg-Kermanac'h N, Semerano L, Naccache J, Brauner M, Falgarone G, Dumont-Fischer D, Guillot X, Valeyre D, Boissier M. Screening for latent tuberculosis in anti-TNF- candidate patients in a high tuberculosis incidence setting. *Int J Tuberc Lung Dis.* 2012 Oct;16(10):1307-14

Santin M, Muñoz L, Rigau D. Interferon- Release Assays for the Diagnosis of Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic Review and Meta-Analysis. *PLoS One.* 2012;7(3):e32482. Epub 2012 Mar 5.

Scivo R, Sauzullo I, Mengoni F, Iaiani G, Vestri A, Priori R, Di Filippo E, Di Franco M, Spinelli F, Vullo V, Mastroianni C, Valesini G. Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. *Clin Rheumatol.* 2012 Nov;31(11):1567-75.

Scivo R, Sauzullo I, Mengoni F, Priori R, Coppola M, Iaiani G, Di Franco M, Vullo V, Mastroianni CM, Valesini G. Mycobacterial Interferon- Release Variations During Longterm Treatment with Tumor Necrosis Factor Blockers: Lack of Correlation with Clinical Outcome. *J Rheumatol.* 2012 Dec 1. [Epub ahead of print]

Shah M, DiPietro D, Greenbaum A, Ketemepi S, Martins-Evora M, Marsiglia V, Dorman S. Programmatic Impact of QuantiFERON-TB Gold In-Tube Implementation on Latent Tuberculosis Diagnosis and Treatment in a Public Health Clinic. *PLoS One.* 2012 May;7(5):e36551. Epub 2012 May 7.

Shu C, Wu V, Yang J, Pan S, Lai T, Wang J, Wang J, Lee L. Predictors and prevalence of latent tuberculosis infection in patients receiving long-term hemodialysis and peritoneal dialysis. *PLoS One.* 2012;7(8):e4259

Siddiqui U, Leano P, Chagan-Yasutan H, Shiratori B, Saitoh H, Ashino Y, Suzuki Y, Hattori T, Telan E. Frequent detection of anti-tubercular-glycolipid-IgG and -IgA antibodies in healthcare workers with late nt tuberculosis infection in the Philippines. *Clin Dev Immunol* 2012;2012:610707.

Sim J, Whang K. Application of the QuantiFERON®-TB Gold test in Erythema Induratum. *J Dermatolog Treat.* 2012 Sep 19. [Epub ahead of print]

Simpson T, Fox J, Crouse K, Field K. Quantitative and qualitative QuantiFERON®-TB Gold In-Tube results among groups with varying risks of exposure to tuberculosis. *Heart Lung.* 2012 Nov;41(6):553-61.

Simpson T, Tomaro J, Jobb C. Implementation of an Interferon-Gamma Release Assay to Screen for Tuberculosis in Refugees and Immigrants. *J Immigr Minor Health.* 2012 Nov 24. [Epub ahead of print]

Singh O, Stober C, Singh A, Blackwell J, Sundar S. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. *PLoS Negl Trop Dis.* 2012 Oct;6(10): Epub 2012 Oct 25.

Sivamani R, Goodarzi H, Garcia M, Raychaudhuri S, Wehrli L, Ono Y, Maverakis E. Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring. *Clin Rev Allergy Immunol.* 2012 Feb 5. [Epub ahead of print]

Stavri H, Murgoci G, Ulea I, Popa L, Popa M. Prospective Comparison of Two Brands of Tuberculin Skin Tests and QuantiFERON-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized Children. *Maedica (Buchar).* 2010 Dec;5(4):271-6.

Slater M, Parsonnet J, Banaei N. Investigation of false-positive results given by the QuantiFERON-TB Gold In-Tube assay. *J Clin Microbiol.* 2012 Sep;50(9). Epub 2012 Jul 11.

Song S, Jeon D, Kim J, Kim Y, Kim S, Cho J, Lee S, Cho W, Park H, Kim Y, Lee M, Lee J. Performance of confirmatory interferon-gamma release assay in school tuberculosis outbreaks. *Chest.* 2012 Apr;141(4):983-8

Sudharshan S, Ganesh S, Balu G, Mahalakshmi B, Therese L, Madhavan H, Biswas J. Utility of QuantiFERON®-TB Gold test in diagnosis and management of suspected tubercular uveitis in India. *Int Ophthalmol.* 2012 ;32(3):217-23. Epub 2012 Apr 15.

Syed Ahamed Kabeer B, Paramasivam P, Raja A. Interferon gamma and interferon gamma inducible protein-10 in detecting tuberculosis infection. *J Infect.* 2012 Jun;64(6):573-9 Trauer JM, Hajkowicz KM, Freeman KG, Krause VL. Feasibility of latent tuberculosis infection diagnosis by interferon- release assay remote from testing facilities. *Commun Dis Intell.* 2011 Jun;35(2):168-71.

Talbot E, Harland D, Wieland-Alter W, Burrer S, Adams L. Specificity of the tuberculin skin test and the T-SPOT.TB assay among students in a low-tuberculosis incidence setting. *J Am Coll Health.* 2012;60(1):94-6.

Theron G, Pooran A, Peter J, van Zyl-Smit R, Mishra K, Meldau R, Calligaro G, Allwood B, Sharma S, Dawson, R Dheda K. Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? *Eur Respir J.* 2012 July;40(1):161-8. Epub 2011 Nov 10.

Tsai T, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen Y, Leonardi C; on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL; Japanese Ustekinumab Study Groups. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. *Br J Dermatol.* 2012 Nov;167(5)

Tuuminen T, Salo E, Kotilainen H, Ruhwald M. Evaluation of the filter paper IP-10 tests in school children after exposure to tuberculosis: a prospective cohort study with a 4-year follow-up. *BMJ Open.* 2012 Dec 4;2(6).

## Journal Article

Uluk T, Allison W, Vince J, Wand H, Tefuarani N, Causer L, Ripa P, Kariko M, Kaminiel O, Cunningham P, Graham S, Kaldor J. Evaluation of an Interferon Gamma Release Assay in Children with Suspected Tuberculosis in Papua New Guinea. *Pediatr Infect Dis J*. 2012 Sep 24. [Epub ahead of print]

Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, Rianda A, Alba L, Giancola ML, Conte A, Schininà V, Rizzi EB, Girardi E, Goletti D. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. *J Infect*. 2012 Jul;65(1):49-59.

Vassilopoulos D, Tsirikla S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. *Clin Vaccine Immunol*. 2011 Dec;18(12):2102-8. Epub 2011 Oct 12.

Verhagen L, Hermans P, Warris A, de Groot R, Maes M, Villalba J, Del Nogal B, van den Hof S, Mughini Gras L, van Soelingen D, Pinelli E, de Waard J. Helminths and skewed cytokine profiles increase tuberculin skin test positivity in Warao Amerindians. *Tuberculosis (Edinb)*. 2012 Nov;92(6):505-12

Vinnard C, Linkin D, Behrman A. Current Approach to Latent Tuberculosis Diagnosis and Treatment among Medical Center Occupational Health Physicians. *Infect Control Hosp Epidemiol*. 2012 Dec.;33(12):1262-5. Epub 2012 Oct 23.

Wang S, Chen J, Zhang Y, Diao N, Zhang S, Wu J, Lu C, Wang F, Gao Y, Shao L, Jin J, Weng X, Zhang W. Mycobacterium tuberculosis RD2 and RD11 antigens Rv1985c and Rv3425 have the promising potential to distinguish active tuberculosis patients from BCG vaccinated individuals. *Clin Vaccine Immunol*. 2012 Nov 7. [Epub ahead of print]

Wang S, Powell D, Nagaraja H, Morris J, Schlesinger L, Turner J. Evaluation of a modified interferon gamma release assay for the diagnosis of latent tuberculosis infection in adult and pediatric populations that enables delayed processing. *Scand J Infect Dis*. 2010 Dec;42(11-12):845-50.

Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Dupon M, Hessamfar M, Ventura M, Malvy D, Dabis F, Pellegrin JL, Moreau JF, Thiébaud R, Pellegrin I; the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Effect of CMV, self-antigen-induced immune response and microbial translocation on chronic immune activation in successfully treated HIV-infected patients, ANRS CO3 Aquitaine cohort. *J Infect Dis*. 2012 Nov 29. [Epub ahead of print]

Whitworth W, Hamilton L, Goodwin D, Barrera C, West K, Racster L, Daniels L, Chuke S, Campbell B, Bohanon J, Jaffar A, Drane W, Maserang D, Mazurek G. Within-subject interlaboratory variability of QuantiFERON-TB gold in-tube tests. *PLoS One*. 2012 Sept 2012;7(9):e43790.

Wiwanitkit V. QuantiFERON-TB Gold test and hemodialysis. *Tuberk Toraks*. 2012;60(1):100.

Wolf T, Goetsch U, Oremek G, Bickel M, Khaykin P, Haberl A, Bellinger O, Gottschalk R, Brodt H, Stephan C. Tuberculosis Skin Test, but not Interferon- $\gamma$ -releasing assays is affected by BCG Vaccination in HIV patients. *J Infect*. 2012 Nov 15. [Epub ahead of print]

Worjolah A, Kato-Maeda M, Osmond D, Rachel Freyre, Aziz N, Cohan D. Interferon Gamma Release Assay Compared With the Tuberculin Skin Test for Latent Tuberculosis Detection in Pregnancy. *Obstetrics and Gynecology*. 2011 Dec;118(6):1363-70

Yano S. Tuberculous hilar lymphadenopathy progressing after isoniazid administration. *J Infect Chemother*. 2012 Jun;18(3):399-402.

Yassin M, Petrucci R, Garie K, Harper G, Arbide I, Aschalew M, Merid Y, Kebede Z, Bawazir A, Abuamer N, Cuevas L. Can interferon-gamma or interferon-gamma-induced-protein-10 differentiate tuberculosis infection and disease in children of high endemic areas? *PLoS One*. 2011;6(9):e23733. Epub 2011 Sep 23.

Yoshikawa H, Baba K. Reproducibility of the QFT-G-IT assay in the contact examination in which a high positive rate was shown independent of contact time. *Kekkaku*. 2012 Apr;87(4):329-35.

Yoshikawa H. Possible presence of a booster effect in people repeatedly exposed to Mycobacterium tuberculosis demonstrated in a Mycobacterium tuberculosis-specific interferon-gamma release assay. *Kekkaku*. 2012 Sep;87(9):557-64. Japanese.

Zanetti C, Peracchi M, Zorzi D, Fiorio S, Fallico L, Palù G. Outbreak of transient conversions of the QuantiFERON-TB Gold In-Tube test in laboratory health care worker screenings. *Clin Vaccine Immunol*. 2012 Jun;19(6):954-60. Epub 2012 Apr 18

Zwerling A, Cojocariu M, McIntosh F, Pietrangelo F, Behr M, Schwartzman K, Benedetti A, Dendukuri N, Menzies D, Pai M. TB screening in Canadian health care workers using interferon-gamma release assays. *PLoS One*. 2012;7(8):e43014



Not a subscriber of QuantiFERON News? Email [news@cellestis.com](mailto:news@cellestis.com) to become one.

Trademarks: QIAGEN® QuantiFERON® (QIAGEN Group)  
QM31635202A © 2012 QIAGEN, all rights reserved.

**Cellestis, a QIAGEN Company**

**North America/South America** ■ QIAGEN Inc ■ +1800 519 4627 ■ [customer.service@cellestis.com](mailto:customer.service@cellestis.com)

**Europe/Middle East/Africa** ■ QIAGEN GmbH ■ +49-2103-291 2000 ■ [europa@cellestis.com](mailto:europa@cellestis.com)

**Australia/New Zealand** ■ Cellestis Limited ■ +61 3 8527 3500 ■ [anz@cellestis.com](mailto:anz@cellestis.com)

**Asia/Pacific** ■ QIAGEN Singapore PTE Ltd ■ +65 6854 8100 ■ [asiapac@cellestis.com](mailto:asiapac@cellestis.com)

